Clinical Trial Update: European Larynx Organ Preservation Study (ELOS) [MK-3475-C44] [Phase 2]

View source ↗

Summary

Phase 2 European Larynx Organ Preservation Study (ELOS) evaluates pembrolizumab (MK-3475) for organ-preserving treatment in squamous cell carcinoma of the head …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypopharyngeal Squamous Cell Carcinoma
• Laryngeal Cancer
• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: University of Leipzig | Conditions: Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Squamous Cell Carcinoma | Phase 2 | Status: RECRUITING